4FDA. Guideline for Drug Master Files[EB/OL ]. http://www. fda.gov/Drugs/GuidanceComplianceRegulatorylnforma- tion/Guidances/ucm122886.htm. 1989-09.2010-11-05.
5European Medicines Agency (EMA). GUIDELINE ON ACTIVE SUBSTANCE MASTER FILE PROCEDURE[EB/ OL]. http : //www.ema.europa.eu/ docs/en_GB/document_ library/Scientific_guideline/2009/09/WCS00002814.pdf. 2004-08-31.2010-11-05.
6Pharmaceuticals and Medical Devices Agency. Guideline on Utilization of Master File for Drug Substances, etc. [EB/OL].http://www.pmda.go.jp/english/service/master_ file.html. 2005-02-10.2010-11-06.
7Pharmaceuticals and Medical Devices Agency. Q&A on the Master File (MF) System, Part Ⅱ (PDF)[EB/OL]. http://www.pmda.go.jp/cnglish/service/master_file.html. 2005-12- 20.2010- 11-06.
9JACKSON K, YOUNG D,PANTS. Drug-excipient interactions and their affect on absorption [ J ]. Pharm Sci Techno Today, 2000,3 ( 10 ) : 336 - 345.
10WANG FJ,SAIDELMG, GAO JM. A mechanistic model of con- trolled drug release from polymer millirods: Effects of excipients and complex binding [ J ]. J Controlled Release, 2007,119 ( 1 ) : 111 - 120.
